Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer

被引：0
|
作者：
Antonarakis, Emmanuel S. [1 ]
机构：
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Oncol & Urol, Baltimore, MD 21287 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2016年 / 14卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：316 / 319
页数：4
相关论文
共 50 条
  • [41] Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer
    Lee, Yan Hiu Athena
    Kai Chan, Jeffrey Shi
    Leung, Chi Ho
    Liu, Alex Qinyang
    Dee, Edward Christopher
    Ng, Kenrick
    Shamash, Johnathan
    Tse, Gary
    Wai Leung, David Ka
    Ng, Chi Fai
    CANCER, 2024, 130 (22) : 3826 - 3835
  • [42] PROGNOSTIC VALUE OF PROSTATE-SPECIFIC ANTIGEN KINETICS DURING TREATMENT OF ADVANCED PROSTATE CANCER WITH ABIRATERONE AND ENZALUTAMIDE: MULTICENTER ANALYSIS
    Kang, Byeong Jin
    Kim, Kyung Hwan
    Ha, Hong Koo
    Ku, Ja Yoon
    Goh, Hyeok Jun
    Kim, Soodong
    Lee, Chan Ho
    JOURNAL OF UROLOGY, 2023, 209 : E489 - E490
  • [43] Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer
    Matsubara, Nobuaki
    Yamada, Yoko
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    Yano, Akihiro
    Kawakami, Satoru
    Otsuka, Masafumi
    Fukasawa, Satoshi
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 142 - 148
  • [44] Enzalutamide as monotherapy for advanced prostate cancer: why not?
    Dellavedova, Tristan
    Boetto, Marta
    Olmedo, Jose
    Pablo Sarria, Juan
    Nobile, Raul
    Ponzano, Rolando
    Quinteros, Leandro
    Malizia Reynoso, Enzo
    Minuzzi, Federico
    ARCHIVOS ESPANOLES DE UROLOGIA, 2016, 69 (07): : 393 - 397
  • [45] Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)
    Pal, Sumanta Kumar
    Patel, Jaymala
    He, Miaoling
    Foulk, Brad
    Kraft, Katherine
    Smirnov, Denis A.
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Bhargava, Vipul
    Jones, Jeremy O.
    CANCER, 2018, 124 (06) : 1216 - 1224
  • [46] Modulation of the Prostate Cancer Resistance Factor Hsp27 by the Chemotherapeutic Drugs Abiraterone, Cabazitaxel, Docetaxel and Enzalutamide
    Kuester, Jennifer H. S.
    Erb, Holger H. H.
    Ahrend, Hannes
    Abazid, Alexander
    Stope, Matthias B.
    ANTICANCER RESEARCH, 2024, 44 (07) : 2815 - 2821
  • [47] Abiraterone improves survival in advanced prostate cancer
    Lyon, Sue
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (11) : 611 - 611
  • [48] New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate
    Akdogan, Bulent
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (02): : 111 - 114
  • [49] Emerging mechanisms of enzalutamide resistance in prostate cancer
    Claessens, Frank
    Helsen, Christine
    Prekovic, Stefan
    Van den Broeck, Thomas
    Spans, Lien
    Van Poppel, Hendrik
    Joniau, Steven
    NATURE REVIEWS UROLOGY, 2014, 11 (12) : 712 - 716
  • [50] Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
    Ying Zhang
    Wei Wei
    Changying Li
    Siyuan Yan
    Shanshan Wang
    Shudong Xiao
    Chenchen He
    Jing Li
    Zhi Qi
    Benyi Li
    Kuo Yang
    Changlin Li
    Cell Death & Disease, 13
12345